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SUMMARY We present a 34-year-old female patient with methotrexate 
unresponsive longstanding plaque psoriasis who developed pustular 
psoriasis ten weeks after initiation of ustekinumab therapy. Given the 
lack of other side effects and the rapid initial response of the underlying 
plaque psoriasis, we opted against discontinuing ustekinumab therapy. 
Topical corticosteroids were added for the management of pustular le-
sions on initial presentation. Given the treatment-resistant nature of our 
patient’s underlying plaque psoriasis, we chose dose-intense regimen 
(every 8 weeks). After successful remission of the pustular lesions, topical 
corticosteroids were discontinued. Following nearly complete clearance 
of the underlying plaque psoriasis, maintenance ustekinumab therapy 
at the recommended 12-week intervals was initiated starting week 28. 
No recurrence of pustular psoriasis was noted during the 18-month 
follow-up. Our experience shows that pustular lesions associated with 
ustekinumab can be successfully managed with topical corticosteroids 
without discontinuing ustekinumab therapy and compromising thera-
peutic benefit seen in the underlying condition.
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InTRoDUCTIon
Traditional treatments for psoriasis have relied 
upon systemic therapy with methotrexate, cyclospo-
rin, oral retinoids and phototherapy. Activation of an 
abnormal immune response, which leads to keratino-
cyte hyperproliferation and epidermal thickening, is 
believed to be at the root of psoriasis (1). Interleukin 
(IL)-12 and IL-23 mRNA has been found to be over-
expressed in psoriatic skin lesions, and gene poly-
morphisms within the genes that encode for IL-12, 
IL-23 or their associated receptor complex compo-
nents are linked to an increased risk of psoriasis (2-
4). Ustekinumab is a monoclonal antibody directed 
against the common p40 subunit of IL-12 and IL-23, 
so, it attenuates the immune cell activation proper-
ties of both IL-12 and IL-23. IL-12 promotes the differ-
entiation of naive CD4+ T lymphocytes to T helper-1 
(Th1) cells, and IL-23 supports the development of 
Th17 cells (5,6). Both Th1 and Th17 cells accumulate 
in psoriatic lesions, where they release an array of 
cytokines such as tumor necrosis factor (TNF)-α, in-
terferon-γ (IFNγ), IL-17 and IL-22, that result in epider-
mal hyperproliferation and development of psoriatic 
plaques (7,8). 
While numerous cases of pustular psoriasis in-
duced by anti-TNF-α therapies have been published, 
there are only two cases of pustular psoriasis flares 
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potentially induced by ustekinumab in the literature 
(9,10). Unlike these two cases, which developed within 
days of the initial dose, we present here a methotrex-
ate-resistant plaque psoriasis patient that developed 
pustular lesions 10 weeks after initial ustekinumab 
therapy. Furthermore, while in the other two cases 
ustekinumab therapy was discontinued on pustule 
presentation, we present an alternative approach of 
successfully managing pustular lesions with topical 
corticosteroids without discontinuing ustekinumab 
therapy and potentially compromising the clinical 
benefit of managing the primary plaque psoriasis.
CASe RePoRT
A 34-year-old woman with longstanding severe 
plaque psoriasis since the age of 10 was admitted to 
the University Department in Skopje because of her 
deteriorating condition (PASI 57.0) while on metho-
trexate. Since the initial diagnosis, the patient had 
received topical corticosteroids, psoralen plus ultra-
violet A irradiation (PUVA), and acitretin. Ustekinum-
ab therapy was administered at weeks 0 and 4 at a 
dose of 45 mg, rapidly reducing disease severity to 
PASI 17.7 by week 4. However, painful erythemosqua-
mous eruptions with pustules on the trunk and limbs 
developed by week 10, and the overall PASI score 
rose to 27.8 (Fig. 1). Our patient had not previously 
experienced flares with a pustular component. No 
laboratory abnormalities at any of the visits or other 
patient-reported adverse events were noted. Bacte-
rial and fungal cultures of the pustules were nega-
tive. Histopathologic examination of a pustular lesion 
showed epidermal psoriasiform hyperplasia with 
parakeratosis, and the presence of both subcorneal 
and spongiform pustules, consistent with pustular 
psoriasis. Topical corticosteroids were added on for 
the local treatment of pustular lesions on their initial 
presentation at week 10. Given the good response of 
primary psoriasis and the lack of other adverse events, 
we chose not to discontinue ustekinumab therapy. 
Moreover, since dose intensification of ustekinumab 
therapy resulted in improved efficacy in the PHOE-
NIX-2 pivotal trial (11), we opted for dose-intense 
therapy every 8 weeks instead of the recommended 
every 12-week regimen, to further control the under-
lying plaque psoriasis in this highly therapy refractory 
patient. By week 12, the pustular psoriatic lesions al-
most completely cleared, the overall PASI score de-
creased to 15.2, and ustekinumab was started every 8 
weeks. By week 20, topical corticosteroid therapy was 
discontinued and the overall PASI score dropped to 
7.6. At week 28, the overall PASI score further dropped 
to 3.9 and ustekinumab dosing was adjusted to every 
12 weeks going forward. No recurrence of pustular le-
sions over the 18-month follow-up was noted.
DISCUSSIon
Only two cases of pustular psoriasis flares po-
tentially induced by ustekinumab have been pub-
lished to date, both developing within days of the 
first dose, one of which observed in a patient with 
prior history of pustular psoriasis flares before receiv-
ing ustekinumab. Importantly, while ustekinumab 
therapy was discontinued in both cases, we opted 
for topical corticosteroids to manage pustular le-
sions without discontinuing ustekinumab therapy. 
We chose not to discontinue ustekinumab therapy in 
order not to compromise the favorable results with 
the underlying methotrexate-resistant plaque psoria-
sis, particularly given the lack of other adverse events. 
We believe that in cases of ustekinumab-associated 
pustular psoriasis, ustekinumab therapy should be 
continued in cases with significant clinical benefit 
in the underlying therapy-resistant plaque psoriasis. 
Furthermore, we recommend using topical cortico-
steroids to successfully manage the pustular lesions 
in such cases.
Given the scant literature on pustular psoriasis af-
ter initiating ustekinumab therapy, there is little sci-
entific data on the molecular causes of this paradoxi-
cal reaction. On the other hand, there is significantly 
more clinical experience with pustular psoriasis after 
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Figure 1. (a) Multiple annular erythematous and desquamating plaques studded with pustules; b) 
close-up of erythematous plaques with numerous pustules (circles and arrows). 
Figure 1. (a) Multiple annular erythematous and des-
quamating plaques studded with pustules; b) close-
up of erythematous plaques with numerous pustules 
(arrows).
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initiating anti-TNF-α therapies, potentially due to the 
greater use of this class of biologics. Importantly, 
however, we were not able to find reports on pustu-
lar psoriasis following therapy with other immuno-
modulatory biological therapies, such as abatacept 
(CTLA-4 inhibitor), anakinra (IL-1R antagonist), basil-
iximab/daclizumab (anti-IL-2Rα mAb), canakinumab 
(anti-IL1β mAb), efalizumab (anti-CD11a mAb) or 
tocilizumab (anti-IL-6R mAb). Therefore, TNF-α inhibi-
tors and ustekinumab could drive a similar molecular 
phenomenon resulting in pustular lesions, which is 
not affected by other immunomodulatory therapies. 
While one such mechanism has been put forth (9), 
we believe that due to the infrequent occurrence of 
these side effects, it will be difficult to gather robust 
scientific evidence to elucidate the underlying mo-
lecular mechanism of this phenomenon.
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